Skip to main content
SpringerLink
Log in
Book cover

Peptides in Oncology I pp 55–68Cite as

LH-RH Agonists in the Treatment of Ovarian Cancer

  • Chapter

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 124))

Abstract

Ovarian carcinoma is one of the most common causes of cancer death in women. During the last decade there have been some advances in surgical, radiation, and cytotoxic chemotherapy of this malignancy. The overall results of these treatments, however, are still disappointing (MRC Gynecologic Cancer Working Party 1990; Averette and Donato 1990; Blackledge and Lawton 1989). Aggressive chemotherapy is burdened with severe acute side effects. In addition, chemotherapy in ovarian cancer is associated with a 4–12 times higher risk of developing leukemia (Kaldor et al. 1990). One trend in modern oncology has been to reduce at least therapy-induced morbidity, if the efficacy of therapy cannot be improved by increased aggressiveness. With breast and endometrial cancer this has been successfully achieved by the introduction of endocrine treatments, both ablative or additive, that take advantage of the sex-steroid dependence of some of these tumors, as reflected by the presence of estrogen and/or progestin receptors (Desombre et al. 1987). Also many ovarian cancers contain significant amounts of sex-steroid receptors. Therapeutic approaches, however, using either antiestrogens or progestins, have not been satisfying (for review, see Desombre et al. 1987; Rao and Slotman 1991).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aten A, Polan ML, Bayless R, Behrman H (1987) A gonadotropin-releasing hormone (GnRH)-like protein in human ovaries: similarity to the GnRH-like ovarian protein of the rat. J Clin Endocrinol Metab 64:1288–1293

    Article  PubMed  CAS  Google Scholar 

  • Averette HE, Donato DM (1990) Ovarian carcinoma, advances in diagnosis, staging and treatment. Cancer 65:703–708

    Article  PubMed  CAS  Google Scholar 

  • Bajusz S, Janaky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, Redding TW, Schally AV (1989 a) Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 86:6313–6317

    Article  PubMed  CAS  Google Scholar 

  • Bajusz S, Janaky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, Redding TW, Schally AV (1989 b) Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6. Proc Natl Acad Sci USA 86:6318–6322

    Article  PubMed  CAS  Google Scholar 

  • Bauknecht T, Runge M, Schwall M, Pfleiderer A (1988) Occurrence of epidermal growth factor receptors (EGF-R) in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol 29:147–157

    Article  PubMed  CAS  Google Scholar 

  • Belisle S, Guevin JF, Bellabarba D, Lehoux JG (1984) Luteinizing hormone releasing hormone binds to enriched placental membranes and stimulates in vitro the synthesis of bioactive human chorionic gonadotropin. J Clin Endocrinol Metab 59:119–126

    Article  PubMed  CAS  Google Scholar 

  • Blackledge G, Lawton FG (1989) Second Birmingham gynecological cancer workshop on second line treatment of ovarian cancer. Br J Cancer 59:657–659

    Article  Google Scholar 

  • Blankenstein MA, Henkelman MS, Klijn JGM (1985) Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 21:1493–1499

    Article  PubMed  CAS  Google Scholar 

  • Bramley TA, Menzies GS, Baird DT (1985) Specific binding of gonadotropin-releasing hormone and an agonist to human corpus luteum homogenates: characterization, properties and luteal phase levels. J Clin Endocrinol Metab 61:834–841

    Article  PubMed  CAS  Google Scholar 

  • Bruckner HW, Motwani BT (1989) Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue. Am J Obstet Gynecol 161:1216–1218

    PubMed  CAS  Google Scholar 

  • Bützow R, Huhtaniemi I, Clayton R, Wahlström T, Andersson LC, Seppälä M (1987) Cultured mammary carcinoma cells contain gonadotropin releasing hormone-like im-munoreactivity, GnRH binding sites and chorionic gonadotropin. Int J Cancer 39:498–501

    Article  PubMed  Google Scholar 

  • Casagrande JT, Louie EW, Pike MC, Roy S, Rock RK, Henderson BE (1979) Incessant ovulation and ovarian cancer? Lancet 2:170–173

    Article  PubMed  CAS  Google Scholar 

  • Casper RF, Erickson GF, Rebar RW, Yen SSC (1982) The effect of luteinizing hormone-releasing factor and its agonist on cultured human granulosa cells. Fertil Steril 37:406–409

    PubMed  CAS  Google Scholar 

  • Clayton RN, Huhtaniemi I (1982) Absence of gonadotropin-releasing hormone receptors in human gonadal tissue. Nature 299:56–59

    Article  PubMed  CAS  Google Scholar 

  • Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk: II. Inferences regarding pathogenesis. JNCI 71:717–721

    PubMed  CAS  Google Scholar 

  • Currie AJ, Fraser HM, Sharpe RM (1981) Human placental receptors for luteinizing hormone releasing hormone. Biochem Biophys Res Commun 89:332–338

    Article  Google Scholar 

  • Desombre ER, Holt JA, Herbst AC (1987) Steroid receptors in breast, uterine and ovarian malignancy. In: Gold JJ, Josinovich JB (eds) Gynecologic endocrinology. Plenum, New York, pp 511–528

    Chapter  Google Scholar 

  • Eidne KA, Flanagan CA, Harris NS, Millar RP (1987) Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell Unes and inhibitory effects of GnRH-antagonists. J Clin Endocrinol Metab 64:425–432

    Article  PubMed  CAS  Google Scholar 

  • Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F, Knuppen R (1989) Gonadotropin-releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 25:215–221

    Article  PubMed  CAS  Google Scholar 

  • Emons G, Pahwa GS, Sturm R, Knuppen R, Oberheuser F (1990) The use of GnRH analogues in ovarian cancer. In: Vickery BH, Lunenfeld B (eds) GnRH analogues in cancer and human reproduction, vol 3. Kluwer, dordrecht, pp 159–170

    Chapter  Google Scholar 

  • Fathalla MF (1971) Incessant ovulation — a factor in ovarian neoplasia? Lancet 2:163

    Article  PubMed  CAS  Google Scholar 

  • Fekete M, Bajusz S, Groot K, Csernus VJ, Schally AV (1989 a) Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes. Endocrinology 124:946–955

    Article  PubMed  CAS  Google Scholar 

  • Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV (1989 b) Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 4:521–528

    Article  PubMed  CAS  Google Scholar 

  • Freedman RS, Saul PS, Edwards CL, Jolies CJ, Gershenson DM, Jones LA, Atkinson EN, Dana WJ (1986) Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study. Cancer Treat Rep 70:369–373

    PubMed  CAS  Google Scholar 

  • Hofmann J, Hölzel F, Hackenberg R, Schulz KD (1989) Characterization of epidermal growth-factor related proteins from human urinary chorionic gonadotropin. J Endocrinol 123:333–340

    Article  PubMed  CAS  Google Scholar 

  • Hsueh AJW, Schaeffer M (1985) Gonadotropin-releasing hormone as a paracrine hormone and neurotransmitter in extrapituitary sites. J Steroid Biochem 23:757–764

    Article  PubMed  CAS  Google Scholar 

  • Iwashita M, Evans MI, Catt KJ (1986) Characterization of a gonadotropin-releasing hormone receptor site in term placenta and chorionic villi. J Clin Endocrinol Metab 62:127–133

    Article  PubMed  CAS  Google Scholar 

  • Jäger W, Wildt L, Lang N (1989) Some observations on the effects of a GnRH analog in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 32:137–148

    Article  PubMed  Google Scholar 

  • Kaldor JM, Day NE, Petterson F, Clarke EA, Pedersen D, Mehnert W, Bell J, Host H, Prior P, Karjalainen S, Neal F, Koch M, Band P, Choi W, Kirn VP, Arslan A, Zarén B, Belch AR, Storm H, Kittelmann B, Fraser P, Stovall M (1990) Leukemia following chemotherapy for ovarian cancer. N Engl J Med 322:1–6

    Article  PubMed  CAS  Google Scholar 

  • Kammerman S, Demopoulos RI, Raphael C, Ross J (1981) Gonadotropic hormone binding to human ovarian tumors. Hum Pathol 12:886–890

    Article  PubMed  CAS  Google Scholar 

  • Kauppila A, Martikainen H, Pentinen J, Reinilä M (1990) GnRH-agonist analogue treatment of ovarian granulosa cell malignancies. Gynecol Endocrinol 4 [Suppl 2]:97

    Google Scholar 

  • Kavanagh JJ, Roberts W, Townsend P, Hewitt S (1989) Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 7:115–118

    PubMed  CAS  Google Scholar 

  • Knecht M, Ranta T, Feng P, Shinohara O, Catt KJ (1985) Gonadotropin-releasing hormone as a modulator of ovarian function. J Steroid Biochem 23:771–778

    Article  PubMed  CAS  Google Scholar 

  • Kullander S, Rausing A, Schally AV (1987) LH-RH agonist treatment in ovarian cancer. In: Klijn JGM (ed) Hormonal manipulation of cancer: peptides, growth factors and new (anti) steroidal agents. Raven, New York, pp 353–356

    Google Scholar 

  • Kvale G, Heuch J, Nüssen S, Beral V (1988) Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer 42:246–251

    Article  PubMed  CAS  Google Scholar 

  • Lamberts SWJ, Timmers JM, Oosterom R, Verleun T, Rommerts FG, de Jong FH (1982) Testosterone secretion by cultured arrhenoblastoma cells: suppression by a luteinizing hormone-releasing hormone agonist. J Clin Endocrinol Metab 54:450–454

    Article  PubMed  CAS  Google Scholar 

  • Latouche J, Crumeyrolle-Arias M, Jordan D, Kopp N, Augendre-Ferrante B, Cedard L, Haour F (1991) GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology 125:1739–1741

    Article  Google Scholar 

  • Lee MT, Liebow C, Kramer AR, Schally AV (1991) Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphoryla-tion and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc Natl Acad Sci USA 88:1656–1660

    Article  PubMed  CAS  Google Scholar 

  • Levy J, Segal T, Wiznitzer A, Insler V, Sharoni Y (1989) Molecular mechanisms of GnRH action on mammary tumors and uterine leiomyomata. In: Vickery BH, Lunenfeld B (eds) GnRH-Analogues in cancer and human reproduction, vol 1. Kluwer, Dordrecht, pp 127–136

    Google Scholar 

  • Li CH, Ramasharma K, Yamashiro D, Chung D (1987) Gonadotropin-releasing peptide from human follicular fluid: isolation, characterization and chemical synthesis. Proc Natl Acad Sci USA 86:959–962

    Article  Google Scholar 

  • Mayer A (1925) Klinik der Ovarialtumoren, Ätiologie. In: Halban J, Seitz L (eds) Biologie und Pathologie des Weibes, vol 5, part 2. Urban und Schwarzenberg, München, pp 877–881

    Google Scholar 

  • Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM (1985) Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313:231–233

    Article  PubMed  CAS  Google Scholar 

  • Mortel R, Satyaswaroop PG, Schally AV, Hamilton T, Ozols R (1986) Inhibitory effect of GnRH superagonist on the growth of human ovarian carcinoma NIH: OVCAR 3 in the nude mouse. Gynecol Oncol 23:254–255

    Article  Google Scholar 

  • MRC Gynecologic Cancer Working Party (1990) An overview in the treatment of advanced ovarian cancer. Br J Cancer 61:495–496

    Article  Google Scholar 

  • Mullen P, Scott WN, Miller WR (1991) Growth inhibition observed following administration of an LH-RH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br J Cancer 63:930–932

    Article  PubMed  CAS  Google Scholar 

  • Nakano R, Kitayama S, Yamoto M, Ooshima A (1989) Localization of gonadotropin binding sites in human ovarian neoplasms. Am J Obstet Gynecol 161:905–910

    PubMed  CAS  Google Scholar 

  • Naor Z (1990) Signal transduction mechanisms of Ca2+ mobilizing hormones: the case of gonadotropin-releasing hormone. Endocr Rev 11:326–353

    Article  PubMed  CAS  Google Scholar 

  • Ohtani K (1990) Effects of gonadotropin on the growth of malignant ovarian neoplasms assessed by subrenal capsule assay. Nippon Sanka Fujinka Gakki Zasshi 42:579–585

    CAS  Google Scholar 

  • Ohtani K, Sakamoto H, Konbai D (1990) Antagonistic effects of GnRH agonist on gonadotropin stimulated proliferation of human ovarian cancer cell line. Gynecol En-docrinol 4 (Suppl 2):98

    Google Scholar 

  • Olshausen R (1877) Die Krankheiten der Ovarien, Ätiologie. In: Billroth T (ed) Handbuch der Frauenkrankheiten, vol 6. Enke, Stuttgart, pp 74–78

    Google Scholar 

  • Olsson JH, Akesson I, Hillensjoe T (1990) Effects of a gonadotropin-releasing hormone agonist on progesterone formation in cultured human granulosa cells. Acta Endocrinol (Copenh) 122:427–431

    CAS  Google Scholar 

  • Pahwa GS, Vollmer G, Knuppen R, Emons G (1989) Photoaffinity labelling of gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Biochem Biophys Res Commun 161:1086–1092

    Article  PubMed  CAS  Google Scholar 

  • Pahwa GS, Kullander S, Vollmer G, Oberheuser F, Knuppen R, Emons G (1991) Specific low affinity binding sites for gonadotropin releasing hormone in human endometrial carcinomata. Eur J Obstet Gynecol Reprod Biol 41:135–142

    Article  PubMed  CAS  Google Scholar 

  • Parmar H, Nicoll J, Stockdale A, Cassoni A, Phillips RH, Lightman SL, Schally AV (1985) Advanced ovarian carcinoma: response to the agonist D-Trp6-LH-RH. Cancer Treat Rep 69:1341–1342

    PubMed  CAS  Google Scholar 

  • Parmar H, Phillips RH, Rustin F, Lightman SL, Hanham JW, Schally AV (1988 a) Therapy of advanced ovarian cancer with D-Trp6-LH-RH (decapeptyl) microcapsules. Biomed Pharmacother 42:531–538

    PubMed  CAS  Google Scholar 

  • Parmar H, Rustin F, Lightman SL, Phillips RH, Hanham JW, Schally AV (1988 b) Response to D-Trp6-luteinizing hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer. B M J 296:1229

    Article  CAS  Google Scholar 

  • Pellicer A, Mirô F (1990) Steroidogenesis in vitro of human granulosa-luteal cells pretreated in vivo with gonadotropin-releasing hormone analogs. Fertil Steril 54:590–596

    PubMed  CAS  Google Scholar 

  • Peterson CM, Zimniski SJ (1990) A long acting gonadotropin-releasing hormone agonist inhibits the growth of a human ovarian epithelial carcinoma (BG-1) heterotransplanted in the nude mouse. Obstet Gynecol 76:264–267

    PubMed  CAS  Google Scholar 

  • Petraglia F, Vaughan J, Vale W (1990) Steroid hormones modulate the release of immunore-active gonadotropin-releasing hormone from cultured human placental cells. J Clin Endocrinol Metab 70:1173–1178

    Article  PubMed  CAS  Google Scholar 

  • Popkin R, Bramley TA, Currie A, Shaw RW, Baird DT, Fraser HM (1983) Specific binding of luteinizing hormone-releasing hormone to human luteal tissue. Biochem Biophys Res Commun 114:750–756

    Article  PubMed  CAS  Google Scholar 

  • Pour PM, Redding TW, Paz-Bouza JI, Schally AV (1988) Treatment of experimental ovarian carcinoma with monthly injection of the agonist D-Trp6-LH-RH: a preliminary report. Cancer Lett 41:105–110

    Article  PubMed  CAS  Google Scholar 

  • Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J (1990 a) The effects of gonadotropin-releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 62:96–99

    Article  PubMed  CAS  Google Scholar 

  • Qayum A, Gullick WJ, Mellon K, Krausz T, Neal D, Sikora K, Waxman J (1990 b) The partial purification and characterization of the GnRH-like activity from prostatic biopsy specimens and prostatic cancer cell lines. J Steroid Biochem Mol Biol 37:899–902

    Article  PubMed  CAS  Google Scholar 

  • Radovick S, Wondisford FE, Nakayama Y, Yamada M, Cutler GB Jr, Weintraub BD (1990) Isolation and characterization of the human gonadotropin-releasing hormone gene in the hypothalamus and placenta. Mol Endocrinol 4:476–480

    Article  PubMed  CAS  Google Scholar 

  • Rajaniemi H, Kauppila A, Rönnberg L, Selander K, Pystynen P (1981) LH (hCG) receptor in benign and malignant tumors of human ovary. Acta Obstet Gynecol Scand Suppl 101:83–86

    Article  PubMed  CAS  Google Scholar 

  • Rao BR, Slotman BJ (1991) Endocrine factors in common epithelial ovarian cancer. Endocr Rev 12:14–26

    Article  PubMed  CAS  Google Scholar 

  • Scambia G, Panici PB, Baiocchi G, Perrone L, Gaggini G, Iacobelli S, Mancuso S (1988) Growth inhibitory effect of LH-RH analogs on human breast cancer cells. Anticancer Res 8:187–190

    PubMed  CAS  Google Scholar 

  • Schlesselman JJ (1989) Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Contraception 40:1–38

    Article  PubMed  CAS  Google Scholar 

  • Seppälä M, Wahlström R (1980) Identification of luteinizing hormone releasing factor and a-subunit of glycoprotein hormones in ductal carcinoma of the mammary gland. Int J Cancer 26:231–233

    Article  Google Scholar 

  • Siler-Khodr TM, Khodr GS (1980) Placental luteinizing hormone releasing factor and its synthesis. Science 207:315–317

    Article  PubMed  Google Scholar 

  • Simon WE, Hölzel F (1979) Hormone sensitivity of gynecological tumor cells in tissue cultures. J Cancer Res Clin Oncol 94:307–323

    Article  PubMed  CAS  Google Scholar 

  • Simon WE, Albrecht M, Hansel M, Dietl M, Hölzel F (1983) Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. JNCI 70:839–845

    PubMed  CAS  Google Scholar 

  • Slotman BJ, Poels LG, Rao BR (1989) A direct LH-RH-agonist action on cancer cells is unlikely to be the cause of response to LH-RH-agonist treatment. Anticancer Res 9:77–80

    PubMed  CAS  Google Scholar 

  • Srkalovic G, Wittliff JL, Schally AV (1990) Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50:1841–1846. Erratum published in: Cancer Res 50:3808

    PubMed  CAS  Google Scholar 

  • Stadel BV (1975) The etiology and prevention of ovarian cancer. Am J Obstet Gynecol 123:772–774

    PubMed  CAS  Google Scholar 

  • Stouffer RL, Grodin MS, Davis JR, Surwitt EA (1984) Investigation of binding sites for follicle-stimulating hormone and ehorionic gonadotropin in human ovarian cancers. J Clin Endocrinol Metab 59:441–446

    Article  PubMed  CAS  Google Scholar 

  • Tan GJS, Biggs JSG (1983) Absence of effect of LH-RH on progesterone production by human luteal cells in vitro. J Reprod Fertil 67:411–413

    Article  PubMed  CAS  Google Scholar 

  • Thompson MA, Adelson MD, Kaufman LM (1991) Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium. J Clin Endocrinol Metab 72:1036–1041

    Article  PubMed  CAS  Google Scholar 

  • Tureck RW, Mastroianni L Jr, Blasco L, Strauß JF III (1982) Inhibition of human granulosa cell progesterone secretion by a gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 54:1078–1080

    Article  PubMed  CAS  Google Scholar 

  • Wilding C, Chen M, Gelman EP (1987) LH-RH agonists and human breast cancer cells. Nature 329:770

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum für Frauenheilkunde und Geburtshilfe, Philipps-Univesität Marburg, Pilgrimstein 3, W-3550, Marburg, Germany

    G. Emons, O. Ortmann & K.-D. Schulz

  2. Klinik für Frauenheilkunde und Geburtshilfe, Medizinische Universität Lübeck, Ratzeburger Allee 160, W-2400, Lübeck, Germany

    G. Emons, O. Ortmann, G. S. Pahwa & F. Oberheuser

Authors
  1. G. Emons
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Ortmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. S. Pahwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Oberheuser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K.-D. Schulz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Universitätsklinikum Essen, Hufelandstraße 55, W-4300, Essen, Germany

    K. Höffken

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Emons, G., Ortmann, O., Pahwa, G.S., Oberheuser, F., Schulz, KD. (1992). LH-RH Agonists in the Treatment of Ovarian Cancer. In: Höffken, K. (eds) Peptides in Oncology I. Recent Results in Cancer Research, vol 124. Springer, Milano. https://doi.org/10.1007/978-88-470-2186-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2186-0_6

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-2188-4

  • Online ISBN: 978-88-470-2186-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation